Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02216630 · ClinicalTrials.gov registry record · Phase 1

Safety and Efficacy of Adipose Derived Stem Cells for Chronic Obstructive Pulmonary Disease

A Phase 1 study of Chronic Obstructive Pulmonary Disease, sponsored by Kimera Society.

Completed
Registry status
Phase 1
Development phase
26
Enrollment target
5
Study locations

NCT02216630: Completed Phase 1 study of Chronic Obstructive Pulmonary Disease, sponsored by Kimera Society.

NCT02216630 is a Phase 1 study of Chronic Obstructive Pulmonary Disease that has completed, run by Kimera Society. The registered enrollment target is 26 participants, below the 1,754-participant average among 86 other Chronic Obstructive Pulmonary Disease trials with a reported enrollment target (99% lower). The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02216630, a Phase 1 study of Chronic Obstructive Pulmonary Disease, has completed, sponsored by Kimera Society.

COMPLETED
Registry status
Phase 1
Development phase
26 participants
Enrollment target
5
Study locations

Study Summary

This will be an open-label, non-randomized multi-center study designed to assess the safety and efficacy of Adipose-derived Stem Cell (ASC) IV implantation. The therapy is composed of cells isolated from a patient's own adipose tissue. Liposuction will be performed to collect the adipose tissue specimen for subsequent processing to isolate the stem cells.

Primary Outcome

The primary efficacy outcome will be a FEV1 decline of approximately or less than 30 ml at 12 month follow-up.

Interventions

  • DRUG Adipose Derived Stem Cell (ADSC) Therapy

Study Locations (5)

Florida

  • Melvin Propis M.D. - Davie

Illinois

  • Chicago - Chicago

Nevada

  • Las Vegas - Las Vegas

New York

  • New York - New York

Texas

  • Dallas - Dallas

Trial Details

FieldValue
Enrollment Target 26 participants
Start Date 2014-08
Est. Completion 2017-07
Phase Phase 1
Kimera Society

1 total trials

What the finished NCT02216630 record still lists

NCT02216630 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 26 participants, a relatively small participant target, below the 1,754-participant average among 86 other Chronic Obstructive Pulmonary Disease trials with a reported enrollment target (99% lower).

The record links to 1 condition, with Chronic Obstructive Pulmonary Disease appearing as the primary indexed condition, and to 1 intervention - of which Adipose Derived Stem Cell (ADSC) Therapy is the first listed.

NCT02216630 lists 5 locations in 5 states (Florida, Illinois, Nevada).

Frequently Asked Questions

What is clinical trial NCT02216630 about?

NCT02216630 is a clinical study titled "Safety and Efficacy of Adipose Derived Stem Cells for Chronic Obstructive Pulmonary Disease". This will be an open-label, non-randomized multi-center study designed to assess the safety and efficacy of Adipose-derived Stem Cell (ASC) IV implantation. The therapy is composed of cells isolated from a patient's own adipose tissue. Liposuction will be performed to collect the adipose tissue spec...

What is the current status of trial NCT02216630?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2014-08. Estimated completion is 2017-07.

What conditions does trial NCT02216630 study?

This clinical trial studies the following conditions: Chronic Obstructive Pulmonary Disease.

What interventions are being tested in trial NCT02216630?

The interventions under investigation include: Adipose Derived Stem Cell (ADSC) Therapy (DRUG).

Who is sponsoring clinical trial NCT02216630?

This trial is sponsored by Kimera Society, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02216630 being conducted?

This trial has 5 study locations across Florida, Illinois, Nevada, New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Chronic Obstructive Pulmonary Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02216630's enrollment target sits among peer trials

26 72nd of 86 higher than 15 of 86 other Chronic Obstructive Pulmonary Disease trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Chronic Obstructive Pulmonary Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02646475 · 26 participants · Phase 1

    Metabolic Effects of Angiotensin-(1-7)

  • NCT03603223 · 26 participants · Phase 2

    Pembrolizumab in Treating Participants With Leukoplakia

  • NCT04063592 · 26 participants · NA

    AMI Construction in Lower Extremity Residual Limbs

  • NCT04906460 · 26 participants · Phase 1

    Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02216630, the US trial registry maintained by the National Library of Medicine. NCT02216630 (small enrollment · multi site footprint · completed) retrieved and formatted by PlainTrial, see methodology.